Product Description
For Malaria (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02149550)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Radboud University Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02149550 |
BMGF2a | N/A |
Completed |
Malaria |
2014-10-01 |
2022-02-10 |
Primary Endpoints|Treatments |
|
NCT01627951 |
TIP3 | N/A |
Completed |
Malaria |
2012-10-01 |
2022-02-10 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|